EconomyNovo Still Has Work to Do to Build Investor Confidence, CEO Says

Novo CEO Mike Doustdar discusses investor confidence, drug testing and the possibility of expanding the company’s obesity offerings. He says Novo should not assume it has a monopoly on good ideas and will look outside the company when strategic or scientific gaps emerge.